COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.

Cencora, Inc. earns a Buy rating with a $337 fair value. Learn how its specialty drug focus and strategic investments drive ...

Cencora, Inc. (NYSE:COR) on Wednesday reported third-quarter 2025 sales increased 8.7% to $80.66 billion, beating the ...

Q3 2025 Earnings Call Transcript August 6, 2025 Cencora, Inc. beats earnings expectations. Reported EPS is $4, expectations were $3.85. Operator: Hello, everyone, and thank you for joining the Cencora ...

Cencora, Inc. ( NYSE: COR) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F. Cleary - Executive VP & CFO Robert P ...

U.S. drug distributor Cencora raised its annual profit forecast on Wednesday after posting quarterly earnings that topped ...

Shares of Cencora Inc. COR shed 2.93% to $283.78 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.73% to 6,345.06 and ...

Bloomberg's large-cap BMVP portfolio delivered positive returns in 2Q but trailed its benchmarks, held back by its defensive tilt during one of the fastest market rebounds on record.

CONSHOHOCKEN, Pa. - On Wednesday, Cencora, Inc. (NYSE: COR) reported third-quarter fiscal 2025 results that exceeded analyst expectations, with adjusted earnings per share of $4.00 beating the ...

Cencora’s forward-looking guidance remains optimistic, with expectations of substantial growth. The company anticipates a 15% to 16% increase in adjusted diluted EPS and consolidated operating income.

DUBLIN, Aug. 4, 2025 /PRNewswire/ -- Mallinckrodt plc today announced that Leslie Donato has been appointed to the Company's ...